MetaVia Gross Margin 2015-2024 | MTVA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

MetaVia gross margin from 2015 to 2024. Gross margin can be defined as a company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage.

MetaVia Gross Margin 2015-2024 | MTVA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

MetaVia gross margin from 2015 to 2024. Gross margin can be defined as a company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$148.2B
Vertex Pharmaceuticals (VRTX)	$120.8B
Bristol Myers Squibb (BMY)	$117.9B
Gilead Sciences (GILD)	$115.1B
CSL (CSLLY)	$87.1B
Regeneron Pharmaceuticals (REGN)	$85.5B
GSK (GSK)	$73B
Argenex SE (ARGX)	$36.8B
Alnylam Pharmaceuticals (ALNY)	$32.7B
BioNTech SE (BNTX)	$27.8B
Illumina (ILMN)	$23.6B
Biogen (BIIB)	$22.8B
BeiGene (BGNE)	$18.3B
Moderna (MRNA)	$16B
Genmab (GMAB)	$14.4B
Incyte (INCY)	$14B
Insmed (INSM)	$13B
BioMarin Pharmaceutical (BMRN)	$12.7B
Bio-Techne Corp (TECH)	$12.3B
Sarepta Therapeutics (SRPT)	$12.1B
Exact Sciences (EXAS)	$11.4B
Vaxcyte (PCVX)	$11.3B
QIAGEN (QGEN)	$10.5B
Exelixis (EXEL)	$10.1B
Bio-Rad Laboratories (BIO.B)	$9.4B
Intra-Cellular Therapies (ITCI)	$8.8B
Roivant Sciences (ROIV)	$8.8B
Repligen (RGEN)	$8.5B
Revolution Medicines (RVMD)	$8B
Ascendis Pharma (ASND)	$7.9B